- Acorda Therapeutics, Inc. A Patient Survey of Mobility and Exercise Issues Among MS Patients [poll]. Poll commissioned by Acorda Therapeutics, Inc. and the Multiple Sclerosis Association of America. February 21, 2008.
- Multiple Sclerosis Association of America Web site. What is Multiple Sclerosis.
- Blight AR. Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury. Brain Res Bull. 1989;22:47-52.
- Waxman SG, Ritchie JM. Molecular Dissection of the Myelinated Axon. Ann Neurol. 1993;33:121-136.
- Bever CT Jr, Judge SIV. Sustained-release fampridine for multiple sclerosis. Expert Opin Invest Drugs. 2009;18:1013-1024.
- a,b. Acorda Therapeutics, Inc. Data on file.
- Goodman A, et al. Sustained-release oral fampridine in multiple sclerosis. Lancet. 2009;373:732-738.
- National Multiple Sclerosis Society. Gait or Walking Problems. 2003; 1-7.
Questions?
1-888-881-1918
1-888-881-1918
AMPYRA® (dalfampridine) Extended Release Tablets is indicated as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.
Important Safety Information
Do not take AMPYRA if you:
- have ever had a seizure
- have certain types of kidney problems
Do not take AMPYRA together with other aminopyridine medications, including compounded 4-AP (sometimes called 4-aminopyridine, fampridine).
AMPYRA can cause seizures. Your chance of having a seizure is higher if you take too much AMPYRA or if you have kidney problems. Before taking AMPYRA tell your doctor if you have kidney problems. Stop taking AMPYRA and call your doctor right away if you have a seizure while taking AMPYRA.
AMPYRA may cause serious side effects, including kidney or bladder infections.
The most common side effects of AMPYRA include: urinary tract infection; trouble sleeping (insomnia); dizziness; headache; nausea; weakness; back pain; problems with balance; multiple sclerosis relapse; burning, tingling or itching of your skin; irritation in your nose and throat; constipation; indigestion; pain in your throat.
Take AMPYRA exactly as your doctor tells you to take it. Do not change your dose of AMPYRA.
Take one tablet of AMPYRA 2 times each day about 12 hours apart. Do not take more than 2 tablets of AMPYRA in a 24-hour period.
Take AMPYRA tablets whole. Do not break, crush, chew or dissolve AMPYRA tablets before swallowing. AMPYRA is released slowly over time. If the tablet is broken, the medicine may be released too fast. This can raise your chance of having a seizure.
If you miss a dose of AMPYRA, do not make up the missed dose. Do not take 2 doses at the same time. Take your next dose at your regular scheduled time. If you take too much AMPYRA, call your doctor or go to the nearest hospital emergency room right away.
Tell your doctor if you are pregnant or plan to become pregnant. It is not known if AMPYRA will harm your unborn baby.
Tell your doctor if you are breast-feeding or plan to breast-feed. It is not known if AMPYRA passes into your breast milk. You should not breast-feed while you are on AMPYRA.
It is not known if AMPYRA is safe and effective in children less than 18 years of age.
For more information, please see the complete Medication Guide.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
 |
AMPYRA® is a registered trademark of Acorda Therapeutics®, Inc. | AMPYRA® is marketed by Acorda Therapeutics®, Inc and manufactured under license from Alkermes Pharma Ireland Ltd. | AMPYRAConnect™ is a trademark of Acorda Therapeutics®, Inc. | The Walking Pill™ is a trademark of Acorda Therapeutics®, Inc. | Take the next step™ is a trademark of Acorda Therapeutics®, Inc. | © 2012 Acorda Therapeutics®, Inc. All rights reserved. | AMP32 |